Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials

Respiratory Medicine

Volumn 112, Issue , 2016, Pages 65-74

  Donohue, James F ^a   Singh, Dave ^b   Munzu, Clara ^c   Kilbride, Sally ^c   Church, Alison ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Bronchodilators; Chronic obstructive pulmonary disease; COPD pharmacology

Indexed keywords

UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; VILANTEROL; BENZYL ALCOHOL DERIVATIVE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHLOROBENZENE; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINUCLIDINE DERIVATIVE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INTENTION TO TREAT ANALYSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SPIROMETRY; TREATMENT DURATION; TREATMENT RESPONSE; VITAL SIGN; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; AGED; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES; TREATMENT OUTCOME;

EID: 84960076299     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2016.01.001     Document Type: Article

References (26)

1. ® prescribing information. http://www.gsksource.com/gskprm/htdocs/documents/INCRUSE-ELLIPTA-PI-PIL.PDF. Date last updated: June 2014. Date last accessed: October 16 2015.
2. ® prescribing information. https://www.gsksource.com/gskprm/htdocs/documents/ANORO-ELLIPTA-PI-MG.PDF. Date last updated: May 2014. Date last accessed: October 16 2015.
3. European Medicines Agency. Anoro: EPAR-product information. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002751/WC500168424.pdf. Date last updated: June 16 2014. Date last accessed: October 16 2015.
4. European Medicines Agency. Incruse: EPAR-product information. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002809/WC500167430.pdf. Date last updated: February 13 2013. Date last accessed: October 16 2015.
5. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html. Date last updated: January 2015. Date last accessed: October 16 2015.
6. B. Celli, G. Crater, S. Kilbride, and et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: A randomized, controlled study Chest 145 2014 981 991
7. J.F. Donohue, M.R. Maleki-Yazdi, S. Kilbride, and et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD Respir. Med. 107 2013 1538 1546
8. M. Decramer, A. Anzueto, E. Kerwin, and et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: Results from two multicentre, blinded, randomised controlled trials Lancet. Respir. Med. 2 2014 472 486
9. J.F. Donohue, D. Singh, C. Munzu, and et al. Evaluating lung function response to umeclidinium/vilanterol (UMEC/VI) 62.5/25mcg, UMEC 62.5mcg and VI 25mcg in COPD patients Eur. Respir. J. 44 Suppl. 56 2014 291
10. B.R. Celli, and W. MacNee ATS/ERS Task Force, Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper Eur. Respir. J. 23 2004 932 946
11. World Medical Association. World Medical Association Declaration of Helsinki-ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended (latest) by the 64th WMA General Assembly, Fortaleza, Brazil, October 2013. http://www.wma.net/en/30publications/10policies/b3/index.html. Date last updated: October 2013. Date last accessed: October 16 2015.
12. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. International Conference on Harmonisation Tripartite Guideline: Guidance for Good Clinical Practice E6 (R1). http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6/E6-R1-Guideline.pdf. Date last updated: June 10 1996. Date last accessed: October 16 2015.
13. D. Renard, M. Looby, B. Kramer, and et al. Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches Respir. Res. 12 2011 54
14. J.F. Donohue, A. Anzueto, J. Brooks, and et al. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD Respir. Med. 106 2012 970 979
15. M. Westwood, J. Bourbeau, P.W. Jones, and et al. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: A systematic review Respir. Res. 12 2011 40
16. N.K. Leidy, L.T. Murray, P. Jones, and et al. Performance of the EXAcerbations of chronic pulmonary disease tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease Ann. Am. Thorac. Soc. 11 2014 316 325
17. I. Tsiligianni, J. Kocks, N. Tzanakis, and et al. Factors that influence disease-specific quality of life or health status in patients with COPD: A review and meta-analysis of Pearson correlations Prim. Care. Respir. J. 20 2011 257 268
18. P. Albert, A. Agusti, L. Edwards, and et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease Thorax 67 2012 701 708
19. K.J. Rhoden, L.A. Meldrum, and P.J. Barnes Inhibition of cholinergic neurotransmission in human airways by beta 2-adrenoceptors J. Appl. Physiol. 65 1988 700 705
20. I. Wessler, T. Reinheimer, G. Brunn, and et al. J-Adrenoceptors mediate inhibition of [3H]-acetylcholine release from the isolated rat and guinea-pig trachea: Role of the airway mucosa and prostaglandins Br. J. Pharmacol. 113 1994 1221 1230
21. T. Ohrui, M. Yanai, K. Sekizawa, and et al. Bronchodilation by beta-adrenergic and anticholinergic agents in patients with chronic obstructive pulmonary disease: Direct measurement of intrabronchial pressure with a new catheter Am. Rev. Respir. Dis. 146 1992 88 91
22. E.D. Bateman, G.T. Ferguson, N. Barnes, and et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: The SHINE study Eur. Respir. J. 42 2013 1484 1494
23. D.A. Mahler, A. D'Urzo, E.D. Bateman, and et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: A randomised, double-blind comparison Thorax 67 2012 781 788
24. D.P. Tashkin, and S.T. Varghese Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender Pulm. Pharmacol. Ther. 24 2011 147 152
25. R. Trivedi, N. Richard, R. Mehta, and et al. Umeclidinium in patients with COPD: A randomised, placebo-controlled study Eur. Respir. J. 43 2014 72 81
26. P.M. Calverley, P.S. Burge, S. Spencer, and et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease Thorax 58 2003 659 664